NF-kappa B Inhibitors Therapeutics Pipeline Analysis of 80+ Companies – GlobeNewswire

December 08, 2020 04:34 ET | Source: DelveInsight Business Research LLP

Los Angeles, Dec. 08, 2020 (GLOBE NEWSWIRE) -- NF-kappa B Inhibitors Therapeutics Pipeline Analysis of 80+ Companies

The Key Players involved in developing the NF-kappa B Inhibitors therapies are AnGes MG, Complexa, Accendatech, Serenex, OncoViRx, Novo Nordisk, Profectus Biosciences, Mitsubishi Tanabe Pharma, ImmuneTarget, Merck Serono, EntreChem, Link Health Group and others.

NF-kappa B Inhibitors Pipeline Insight, 2020 report by DelveInsight provides extensive insights around 80+ Companies and 80+ Pipeline Drugs based on NF-kappa B Inhibitors pipeline landscape. It includes the pipeline drug profiles, covering clinical and non-clinical stage products.

NF-kappa B Inhibitors Clinical Trial Report key features

Have a question about NF-kappa B Inhibitors Clinical Trial Analysis? Download sample report https://www.delveinsight.com/sample-request/nf-kappa-b-inhibitors-pipeline-insight

The nuclear factor-B (NF-B) signalling pathway performs a significant role in the development, maintenance, and progression of most chronic diseases. NF-B controls the expression of genes involved in a myriad of physiological responses, comprising immune-inflammatory responses, acute-phase inflammatory responses, oxidative stress responses, cell adhesion, differentiation, and apoptosis. Evidence reveals that NF-kB acts as a link between inflammation and cancer progression, making NF-B vital to and a potential drug target in haematological malignancies and solid tumors.

NF-kappa B Inhibitors Upcoming Drugs

AnGes MG is developing AMG 0101 for the Atopic Dermatitis treatment. It is currently in phase III stage of development.

CXA-10 by Complexa is an oral nitrated fatty acid compound that acts via a constellation of actions including Upregulation of Nrf2 pathways; Inhibition of NF-Kappa B and TLR4; Inhibition of Xanthine Oxidoreductase; and Increasing the expression of heat shock proteins.

ACT001 is an investigational product recently completed testing in phase I clinical studies.

Accendatech designed and developed ACT001; the drug is specifically used to target brain tumour for treatment of Glioblastoma Multiforme (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG).

For additional product profiles, request @ https://www.delveinsight.com/sample-request/nf-kappa-b-inhibitors-pipeline-insight

Scope of NF-kappa B Inhibitors Pipeline Therapeutics report

NF-kappa B Inhibitors Pipeline Products:

NF-kappa B Inhibitors Companies:

Key Questions regarding Current NF-kappa B Inhibitors Treatment Scenario and Emerging Therapies Answered in the report

Table of Contents

Browse Detailed TOC, Emerging Drugs and Key Companies @ https://www.delveinsight.com/sample-request/nf-kappa-b-inhibitors-pipeline-insight

Related Reports

PARP Inhibitors Inhibitor Pipeline Insight, 2020 report by DelveInsight proffers complete insights into the pipeline therapeutics scenario.

Signal Transducer And Activator Of Transcription 3/5 (STAT3/5) Inhibitor Pipeline Insight, 2020 report by DelveInsight provides detailed insights of the pipeline.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.

View post:
NF-kappa B Inhibitors Therapeutics Pipeline Analysis of 80+ Companies - GlobeNewswire